These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22687893)

  • 1. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
    J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
    Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
    Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
    Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Maganda BA; Minzi OM; Kamuhabwa AA; Ngasala B; Sasi PG
    Malar J; 2014 May; 13():205. PubMed ID: 24885714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
    Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
    PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
    Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
    Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
    Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.
    Lamorde M; Byakika-Kibwika P; Mayito J; Nabukeera L; Ryan M; Hanpithakpong W; Lefèvre G; Back DJ; Khoo SH; Merry C
    AIDS; 2013 Mar; 27(6):961-965. PubMed ID: 23698061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study.
    Lefèvre G; Bhad P; Jain JP; Kalluri S; Cheng Y; Dave H; Stein DS
    Malar J; 2013 Sep; 12():312. PubMed ID: 24010572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
    Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
    Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
    Mwesigwa J; Parikh S; McGee B; German P; Drysdale T; Kalyango JN; Clark TD; Dorsey G; Lindegardh N; Annerberg A; Rosenthal PJ; Kamya MR; Aweeka F
    Antimicrob Agents Chemother; 2010 Jan; 54(1):52-9. PubMed ID: 19841149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
    Lefèvre G; Carpenter P; Souppart C; Schmidli H; McClean M; Stypinski D
    Br J Clin Pharmacol; 2002 Nov; 54(5):485-92. PubMed ID: 12445027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
    Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
    BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
    Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.